SIFI (Societa Industria Farmaceutica Italiana) S.p.A.
12 articles about SIFI (Societa Industria Farmaceutica Italiana) S.p.A.
-
AffaMed Technologies Announces Licensing of EVOLUX®- a novel extended monofocal intraocular lens (IOL) designed to provide better intermediate vision and equivalent distance vision when compared to a standard monofocal IOL
10/10/2023
AffaMed Technologies, a joint venture established between AffaMed Therapeutics and SIFI S.p.A., announced it has entered into a licensing agreement with SIFI under which AffaMed has obtained the exclusive rights to manufacture, develop and commercialize EVOLUX®, a novel extended monofocal intraocular lens, in Greater China.
-
SIFI Announces License Agreement With Avanzanite Bioscience for Akantior®
1/10/2023
SIFI announced that it has partnered with Avanzanite Bioscience, a Dutch specialty pharmaceutical company, to exclusively commercialize and distribute AKANTIOR® in 26 Countries within the European Economic Area and Switzerland.
-
SIFI Reports Detailed Positive Results and New Data from the Completed Phase 3 Trial of AKANTIOR® in Patients with Acanthamoeba Keratitis presented at the American Academy of Ophthalmology Annual Meeting in Chicago
10/13/2022
SIFI S.p.A reported the presentation of positive results from the positive Phase 3 Study [NCT03274895] of AKANTIOR®, an investigational anti-amoebic polymer, an orphan drug, for the treatment of acanthamoeba keratitis.
-
SIFI Receives Favorable Feedback From the US FDA on Akantior® for the Treatment of Acanthamoeba Keratitis
5/16/2022
SIFI S.p.A., a leading international ophthalmic company headquartered in Italy, announced that it received favorable and supportive feedback from the United States Food and Drug Administration through a 'Type B' meeting held in early May regarding its potential regulatory application of AKANTIOR® for the treatment of acanthamoeba keratitis.
-
SIFI Announces the Granting of a Second FDA Orphan Drug Designation for Polihexanide in Fungal Keratitis
3/14/2022
SIFI S.p.A., a leading international ophthalmic pharmaceutical company, announced that the U.S. Food and Drug Administration has approved the company's Orphan Drug Designation application for its investigational anti-infective polymer polihexanide for the treatment of fungal keratitis.
-
SIFI Announces Positive Topline Results of the Pivotal Phase III Study of Polihexanide for the Treatment of Acanthamoeba Keratitis
10/19/2021
SIFI, a leading international ophthalmic company, announced that the pivotal Phase III study on polihexanide 0,08% monotherapy in adults and adolescents with Acanthamoeba keratitis, met its primary endpoint of 'clinical resolution rate over a 12-month timeframe'.
-
SIFI (Societa Industria Farmaceutica Italiana) Announces the Publication of its Phase I Study on Polihexanide in the British Journal of Ophthalmology
2/1/2021
SIFI, a leading ophthalmic company, announced today the publication of clinical results from its Phase I trial of polihexanide in healthy volunteers.
-
SIFI Announces the Publication of its Phase I Study on Polihexanide in the British Journal of Ophthalmology
2/1/2021
SIFI, a leading ophthalmic company, announced the publication of clinical results from its Phase I trial of polihexanide in healthy volunteers.
-
SIFI Launches SYNFO, A New Treatment For Dry Eye Disease
1/7/2021
SIFI, a leading international ophthalmic company, announces the launch of SYNFO, a novel medical device representing the latest addition to its comprehensive dry eye portfolio.
-
Sifi Launches Well Fusion, A Novel Presbyopia Correcting System
12/21/2020
SIFI, a leading international eye care company, announces the launch of the WELL FUSION™ system and the Mini WELL PROXA® intraocular lens, offering a novel solution that provides cataract patients the option to treat presbyopia with spectacle-free uninterrupted high-quality vision at all distances and in all lighting conditions.
-
SIFI completes enrollment of the Phase III Study of polihexanide 0.08% for the treatment of Acanthamoeba keratitis
11/19/2020
SIFI, a leading ophthalmic company, announced that it has achieved the full enrollment of 135 patients with Acanthamoeba keratitis in its pivotal Phase III clinical trial.
-
Knight Therapeutics and SIFI S.p.A. Announce Filing of New Drug Submission for NETILDEX in Canada
2/15/2018
Knight Therapeutics and SIFI S.p.A. today announced that Knight's New Drug Submission (NDS) for NETILDEX has been accepted for review by Health Canada.